Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
NCT01653106 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148
Last updated 2017-06-27
Summary
The purpose of this study is to compare the effect of short-term (2 hours/120 minutes) and long-term (6 hours/360 minutes) schedules of crushed ice therapy (cryotherapy). Patients that receive high dose melphalan for bone marrow transplantation commonly develop significant mouth pain and sores (oral mucositis) unless cryotherapy is utilized. The goal of this study is to scientifically determine (using randomization and a larger sample size) if a short-term schedule is as effective as the standard long-term schedule in preventing, or minimizing the symptoms involved with oral mucositis. The study is also trying to determine the best dose of melphalan and how patient's body breaks down melphalan and will obtain blood through central venous catheter to measure the amount of melphalan in patient's blood at specific times after the melphalan is infused
Conditions
- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma
Interventions
- PROCEDURE
-
cryotherapy
Receive shaved ice
- OTHER
-
questionnaire administration
Participate in PROMS
- OTHER
-
pharmacological study
Correlative studies
Sponsors & Collaborators
-
Ohio State University Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Craig Hofmeister, MD · Ohio State University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2014-05-31
- Completion
- 2015-03-31
Countries
- United States
Study Locations
More Related Trials
-
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
NCT00006122 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia
NCT00806325 ·Status: COMPLETED
-
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01707004 ·Status: COMPLETED ·Phase: PHASE2
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
NCT02446964 ·Status: COMPLETED ·Phase: PHASE1
-
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00658814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00002805 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00124644 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00002719 ·Status: COMPLETED ·Phase: PHASE3
-
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
NCT01801046 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00053131 ·Status: COMPLETED ·Phase: PHASE2
-
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
NCT03696537 ·Status: TERMINATED ·Phase: PHASE1
-
Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia
NCT00005801 ·Status: COMPLETED ·Phase: PHASE2
-
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
NCT06572631 ·Status: WITHDRAWN ·Phase: PHASE1
-
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT01807091 ·Status: COMPLETED ·Phase: NA
-
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
NCT01174888 ·Status: COMPLETED ·Phase: PHASE1
-
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
NCT01252667 ·Status: COMPLETED ·Phase: PHASE2
-
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT02122081 ·Status: COMPLETED ·Phase: PHASE1
-
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
NCT00322101 ·Status: COMPLETED ·Phase: PHASE3
-
Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01085617 ·Status: COMPLETED
-
Lenalidomide Plus Chemotherapy for AML
NCT01681537 ·Status: COMPLETED ·Phase: PHASE1
-
Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
NCT02587871 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
NCT02795520 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150 ·Status: COMPLETED
-
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
NCT00070174 ·Status: COMPLETED ·Phase: PHASE2
-
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02666950 ·Status: COMPLETED ·Phase: PHASE2